Bristol-Myers Squibb, Bayer team up on Opdivo-Stivarga combo in colorectal cancer

BMS' Opdivo is currently approved for just 5% of colorectal cancer patients. (Bayer)

Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo—and it’s bringing in Bayer to help.

The two companies, along with Bristol partner Ono Pharmaceutical, have joined forces in a clinical pact to test the immuno-oncology star alongside Bayer's Stivarga in patients with microsatellite stable metastatic colorectal cancer, which represents about 95% of cases.

The companies stayed tight-lipped on the collaboration’s terms, but they did note that they’ll be plotting an indication-seeking trial for the drug duo.


De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

Wednesday, July 8, 2020 | 11am EST / 8am PST

This webinar will describe strategies to mitigate risks, reduce attrition and help improve the quality and safety of your drug candidate.

RELATED: Bristol-Myers Squibb's Opdivo nabs MSI-H colorectal cancer nod, but it can't match Keytruda's umbrella approval

Right now, Opdivo bears a green light to treat a sliver of the colorectal cancer patient population. Nearly two years ago, the FDA gave the treatment a go-ahead in those with microsatellite instability-high (MSI-H) metastatic colorectal cancer, a rare tumor type that makes sufferers less likely to respond to conventional chemo.

In the broader colorectal cancer group, though, “I-O monotherapy treatment approaches have shown limited activity,” Bristol noted, “thus, the need for additional treatment options including combination approaches remains high.”

Meanwhile, while Stivarga already has an OK for previously treated colorectal cancer that has spread to other parts of the body, it too could benefit from another indication in the disease. While its sales grew overall in 2018, in the U.S., sales declined thanks to “a highly competitive market environment.” Its competition in colorectal cancer includes Otsuka’s Lonsurf, another drug for previously treated patients whose cancer has spread.

RELATED: Bristol-Myers' I-O star Opdivo steps up to challenge Bayer's Stivarga in liver cancer

Outside of colorectal cancer, though, it’s Opdivo itself that’s part of Stivarga’s problem. Both drugs are approved for liver cancer patients who have already received Bayer’s Nexavar, and they’re duking it out in that arena.

For its part, Bayer is looking at new cancer types for Stivarga, too. It recently opened up U.S. trial enrollment for a study program that will test the drug in glioblastoma patients.

Suggested Articles

Novartis and Civica Rx are patterning up to shore up supply of six key generic injectables used in acute care settings in hospitals.

EU health commissioner Stella Kyriakides reportedly spoke with Gilead execs to iron out a deal to secure remdesivir supply for 16 EU countries.

Under a $1.6 billion deal with the U.S. government, Novavax has pledged to start producing 100 million doses of a COVID-19 vaccine later this year.